
Topic
Surgical Oncology
Podcasts
Tumor Board # 92Nov 17, 2026Multidisciplinary Approaches in Pancreatic Cancer Care

At Cedars-Sinai, the time from a pancreatic cancer diagnosis to the first dose of chemotherapy fell from about a month to 14 days, and trial enrollment nearly tripled, once every specialist started seeing the patient in the same room on the same day. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar of Cedars-Sinai is joined by surgical oncologist Dr. Adam Yopp, chief of surgical oncology at UT Southwestern, and GI medical oncologist Dr. Arsen Osipov of Cedars-Sinai to compare how their same-day multidisciplinary clinics run and what every clinic needs, from an experienced pancreatic surgeon and a radiation oncologist to genetic counseling, an early dietitian visit, and supportive care. They also explain how virtual tumor boards, same-week biopsy slots, and outreach networks bring community oncologists in Texas and California into the plan, and weigh whether pancreatic cancer care should be regionalized, as it is in parts of Canada.
Tumor Board # 89Nov 2, 2026Perioperative Management of Pancreatic Cancer

Most patients with localized pancreatic cancer already have disease the scans cannot see, which is why these GI oncologists treat chemotherapy before surgery as a test of tumor biology. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar leads a tumor board with GI medical oncologists Dr. Arsen Osipov and Dr. Daniel Ahn on the perioperative management of pancreatic cancer. They explain why nearly every patient with localized disease now starts with chemotherapy rather than surgery, which red flags such as an elevated CA 19-9, enlarged lymph nodes, or profound weight loss point to hidden micrometastatic disease, and why an 80-year-old can still be a candidate for FOLFIRINOX when biological age outweighs chronological age.
Tumor Board # 85Oct 13, 2026Perioperative Management in Upper GI Cancers

How do you choose between perioperative chemotherapy and trimodality therapy for a patient with localized upper GI cancer, and what has the newest data actually settled? On this episode of BackTable Tumor Board, host Dr. Kate Baker interviews Dr. Dani Castillo, a medical oncologist at City of Hope in Duarte, California, and Dr. Alexandra Gangi, a gastrointestinal surgical oncologist at Cedars-Sinai in Los Angeles, about everything that happens between a new diagnosis and a resection in localized esophageal, gastroesophageal junction and gastric cancer. They cover diagnostic workup, Siewert classification, staging laparoscopy, histology, biomarker testing, surgical candidacy, and the challenges of nutrition and prehabilitation.
Tumor Board # 82Sep 22, 2026Advances in Perioperative Colorectal Cancer Management

How much of perioperative colorectal cancer management has changed in just one year, and what does it mean for patient care? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Alexandra Gangi to review the latest practice-changing data in colon and rectal cancer. They discuss observation versus maintenance immunotherapy in MSI-high disease, the CHALLENGE trial's surprising results on exercise and disease-free survival, and the evolving role of ctDNA and local therapies after liver metastasis resection.
Urology # 327Sep 1, 2026Clinical Approaches to Testicular Cancer Management

What are the key considerations for choosing between surveillance, surgery, and chemotherapy in testicular cancer? On this episode of BackTable Urology, host Dr. Rich Matulewicz is joined by Dr. Sean Kern and Dr. Sam Funt for an in-depth discussion on clinical approaches to testicular cancer. They start with a real-world case, reviewing initial evaluation, imaging, tumor markers, and counseling on fertility, body image, and hypogonadism. The conversation highlights how nuanced patient selection influences decisions between surveillance, surgical intervention, and adjuvant chemotherapy.
Urology # 317Jul 17, 2026Focal Therapy in Prostate Cancer Treatment

Can focal therapy truly “thread the needle” between active surveillance and radical prostate cancer treatment? In this episode of BackTable Urology, host Dr. Tiwa Akinsola is joined by Dr. George Schade from the University of Washington to explore focal therapy as a middle ground between active surveillance and radical treatments. Dr. Schade reviews non-radiation energy modalities including HIFU, TULSA/HI-DU, cryotherapy, and irreversible electroporation, highlighting patient selection, institutional experience, technical nuances, and quality-of-life outcomes from recent trials.
Vascular & IR # 660Jul 3, 2026Techniques & Outcomes of Portal Vein Embolization

How is portal vein embolization (PVE) pushing the boundaries of liver tumor resectability, and what does it take to induce hypertrophy without compromising the remnant liver? In this episode of the BackTable Podcast, interventional radiologist Dr. David Madoff of Yale University joins Dr. Michael Barraza to discuss the pathophysiological rationale, technical considerations, and emerging clinical paradigms of performing PVE to augment the future liver remnant (FLR) prior to resection and reduce the risk of postoperative liver failure.
Urology # 310Jun 18, 2026Bladder Cancer Risk Stratification: Best Practices

Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes.
Tumor Board # 64Jun 9, 2026Evolving Perioperative Management Strategies for Gastric & GE Junction Cancers

Is personalized, surgery-sparing treatment becoming a reality for patients with gastric adenocarcinoma? In this episode of BackTable Tumor Board, Dr. Eric Lander and Dr. Michael Gibson break down the rapidly changing landscape of treatment for resectable gastric and gastroesophageal junction adenocarcinoma. They trace the evolution from surgery as the standard, through difficult postoperative chemoradiation and perioperative chemotherapy (MAGIC, FLOT4), to the new strategies that are moving beyond traditional chemoradiation in the wake of the ESOPEC trial.
Tumor Board # 62Jun 2, 2026Advancements in Managing Locally Advanced Pancreatic Cancer

Can a tumor deemed permanently unresectable actually be downstaged to surgery? In this episode of BackTable Tumor Board, host Dr. Zach Berman (interventional radiologist, UC San Diego) is joined by Dr. Rebekah White (surgical oncologist) and Dr. Michael Sherer (radiation oncologist) to discuss the complexities of managing locally advanced, unresectable pancreatic cancer and evaluate how individualized patient factors, treatment response, and multidisciplinary expertise can turn inoperable tumors into surgical candidates.
Vascular & IR # 644May 12, 2026Optimizing Liver Transplant Pathways & Decision-Making

A high-functioning HCC tumor board can turn complex transplant decisions into coordinated treatment plans that account for liver reserve, tumor biology, and evolving biomarkers. In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, abdominal transplant surgeon Dr. Ari Cohen (Ochsner Health) and transplant hepatologist Dr. Neil Mehta (UCSF) join host Dr. Kavi Krishnasamy to map out strategies for effective multidisciplinary treatment and transplantation planning in HCC.
Vascular & IR # 642May 7, 2026Exploring CPN & Radiation Segmentectomy in Liver Cancer

Complete pathologic necrosis (CPN) rates above 90%? This week’s BackTable episode from the 2026 HCC Creator Weekend™ is cracking the code on complete tumor kill in hepatocellular carcinoma (HCC) bridging therapy. Host Dr. Kavi Krishnasamy is joined by Dr. Zach Berman and Dr. Beau Toskich to break down the latest multi-center research from COBRAS (Consortium on Bridging Radiation Segementectomy with Glass Microspheres Before Transplant), setting a new standard for bridging therapy that offers actionable strategies to improve outcomes.
Tumor Board # 54Apr 7, 2026Clinical Advances in Muscle Invasive Bladder Cancer

Don’t miss the “curative window”! This episode takes a closer look at how evolving perioperative strategies and biomarker integration are changing bladder cancer care, with a focus on preserving opportunities for cure. Dr. Jun Gong hosts Dr. Tyler Stewart to review key bladder cancer updates from ASCO Genitourinary Cancers Symposium 2026.
Tumor Board # 42Jan 6, 2026Neoadjuvant Therapy in Resectable Pancreatic Cancer

For the small subset of pancreatic cancer patients whose cancer is detected early and remains localized, there are now opportunities to offer treatment and improve outcomes. In this episode of the BackTable Tumor Board Podcast, Ochsner medical oncologist Dr. Jonathan Mizrahi and MD Anderson surgical oncologist Dr. Rebecca Snyder discuss the contemporary management of localized pancreatic cancer.
Vascular & IR # 591Nov 21, 2025NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.
Tumor Board # 35Nov 14, 2025NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.
ENT & Allergy # 247Nov 11, 2025Keynote-689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer

When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.
Tumor Board # 33Nov 4, 2025Keynote-689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer

When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.
ENT & Allergy # 245Oct 28, 2025Understanding Keynote-689: Immunotherapy for Head & Neck Cancer

While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.
Tumor Board # 32Oct 28, 2025Understanding Keynote-689: Immunotherapy for Head & Neck Cancer

While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.
Tumor Board # 30Oct 7, 2025NMIBC Tumor Board: Nuances in Management

When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios.
Tumor Board # 10Mar 18, 2025Collaborative Oncology: Surgeon’s Perspective & Role in Locoregional Therapy

Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy.
Vascular & IR # 524Mar 11, 2025Collaborative Oncology: Surgeon’s Perspective & Role in Locoregional Therapy

Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy.
Bone & Sports # 7Jun 18, 2023Desmoid Tumors: IR's Role in Diagnosis and Management

In this episode, host Dr. Jacob Fleming interviews Dr. Jack Jennings about cryoablation, multidisciplinary care, and practice building for the treatment of desmoid tumors.